司美格鲁肽与替尔泊肽治疗糖尿病和肥胖患者后的神经退行性变与卒中
该回顾性队列研究基于TriNetX美国网络2017年12月1日至2024年6月30日电子健康记录,纳入40岁及以上2型糖尿病合并肥胖、无既往神经退行性或脑血管疾病的成人,比较司美格鲁肽或替尔泊肽(GLP-1RA组)与其他降糖药。倾向评分匹配后每组30430例,随访7年,GLP-1RA组痴呆风险HR 0.63(95%CI 0.50-0.81)、卒中风险HR 0.81(95%CI 0.70-0.93)、全因死亡风险HR 0.70(95%CI 0.63-0.78)均较低,帕金森病和脑出血风险无显著差异。亚组分析显示60岁及以上、女性、BMI 30至40的患者获益更大。作者认为这些发现提示GLP-1RA可能具有降糖之外的神经保护和脑血管获益,需进一步试验确认。
要点
- 倾向评分匹配后每组30430例,GLP-1RA组痴呆风险HR 0.63(95%CI 0.50-0.81),低于其他降糖药组。
- GLP-1RA组卒中风险HR 0.81(95%CI 0.70-0.93),全因死亡风险HR 0.70(95%CI 0.63-0.78),均低于其他降糖药组。
- 帕金森病和脑出血风险在GLP-1RA组与其他降糖药组间无显著差异。
- 亚组分析显示60岁及以上、女性、BMI 30至40的患者获益更大。
- 作者认为GLP-1RA可能具有降糖之外的神经保护和脑血管获益,需进一步试验确认。
适用人群与场景
- 40岁及以上2型糖尿病合并肥胖的成人,来自TriNetX美国网络电子健康记录,排除既往神经退行性或脑血管疾病者。
研究设计与关键结果
- 回顾性队列研究,基于TriNetX美国网络2017年12月1日至2024年6月30日数据,倾向评分匹配后GLP-1RA组与其他降糖药组各30430例,GLP-1RA组平均年龄57.9(SD 9.9)岁、女性50.2%,其他降糖药组平均年龄58.0(SD 10.8)岁、女性51.4%。
- 随访7年,GLP-1RA组较其他降糖药组痴呆风险降低(HR 0.63;95%CI 0.50-0.81)、卒中风险降低(HR 0.81;95%CI 0.70-0.93)、全因死亡风险降低(HR 0.70;95%CI 0.63-0.78)。
- 帕金森病和脑出血风险在两组间无显著差异。
- 亚组分析显示60岁及以上、女性、BMI 30至40的患者获益更大。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为GLP-1RA(司美格鲁肽和替尔泊肽)可能具有降糖之外的神经保护和脑血管获益,需进一步试验确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Glucagon-like peptide 1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, provide cardiometabolic benefits to patients with type 2 diabetes and obesity, but their potential benefits in mitigating neurodegenerative and cerebrovascular diseases remain unclear.
OBJECTIVE: To evaluate the association of semaglutide and tirzepatide with the incidence of dementia, Parkinson disease, ischemic stroke, intracerebral hemorrhage, and all-cause mortality compared with other antidiabetic drugs in adults with type 2 diabetes and obesity.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study analyzed electronic health record-based data from the TriNetX US network (December 1, 2017, to June 30, 2024) in adults aged 40 years or older with type 2 diabetes and obesity initiating semaglutide, tirzepatide, or other antidiabetic drugs, excluding those with prior neurodegenerative or cerebrovascular diseases. Propensity score matching was used to balance the baseline characteristics.
EXPOSURES: Patients treated with antidiabetic drugs were categorized as GLP-1RA (semaglutide or tirzepatide) or other antidiabetic drug (biguanides, sulfonylureas, dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, thiazolidinediones, and α-glucosidase inhibitors) users.
MAIN OUTCOMES AND MEASURES: The primary outcomes were the incidence of neurodegenerative diseases (dementia, Parkinson disease, and mild cognitive impairment) and cerebrovascular (stroke and intracerebral hemorrhage) diseases, while the secondary outcome was all-cause mortality. Cox proportional hazard models were used to estimate hazard ratios (HRs) with 95% CIs.
RESULTS: A total of 60 860 adults with type 2 diabetes and obesity were included, with 30 430 each in the GLP-1RA group (mean [SD] age, 57.9 [9.9] years; 50.2% female) and the other antidiabetic drug group (mean [SD] age, 58.0 [10.8] years; 51.4% female) after propensity score matching. During a 7-year follow-up, GLP-1RA users had a lower risk of dementia (HR, 0.63; 95% CI, 0.50-0.81), stroke (HR, 0.81; 95% CI, 0.70-0.93), and all-cause mortality (HR, 0.70; 95% CI, 0.63-0.78), with no significant differences in the risk of Parkinson disease or intracerebral hemorrhage. Subgroup analyses revealed greater benefits in patients aged 60 years or older, women, and patients with a body mass index of 30 to 40.
CONCLUSIONS AND RELEVANCE: In this cohort study, the use of GLP-1RAs semaglutide and tirzepatide was associated with a lower risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. These findings suggest potential neuroprotective and cerebrovascular benefits of GLP-1RAs beyond glycemic control, warranting further trials to confirm these outcomes.
参考来源
- Lin HT, Tsai YF, Liao PL, et al. Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. JAMA Netw Open. 2025. PMID: 40663350. doi:10.1001/jamanetworkopen.2025.21016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。